New Delhi: QuintilesIMS has announced that it will be changing its name to IQVIA, a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients, effective November 6, 2017. Beginning on November 15, 2017, equity shares of the company will trade on the NYSE under the new name and new ticker symbol “IQV.” Until then, IQVIA will continue to be listed under QuintilesIMS and symbol “Q” per the listing notification requirements of the NYSE.
IQVIA’s client solutions are powered by the IQVIA CORE. The CORE enables IQVIA to provide customized solutions for clients leveraging the world’s largest curated healthcare information source, advanced analytics, leading technologies and extensive industry knowledge across diseases, geographies, and scientific methods. It fuels the company’s approach to human data science, including faster, more predictable clinical development, innovative approaches to generating real-world evidence, machine learning to improve patient care, and strategies for precision commercial engagement. The seamless integration of these elements from molecule to market enables our customers to drive enhanced value, access and health outcomes around the world.
“Today is a defining moment for our organization as we introduce a new name that aligns with our vision to help stakeholders drive healthcare forward,” said IQVIA Chairman and CEO Ari Bousbib.